Altered levels of fecal chromogranins and secretogranins in IBS: Relevance for pathophysiology and symptoms

American Journal of Gastroenterology

Volumn 107, Issue 3, 2012, Pages 440-447

  Öhman, Lena ^a   Stridsberg, Mats ^b   Isaksson, Stefan ^a   Jerlstad, Pernilla ^a   Simrén, Magnus ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; CHROMOGRANIN; CHROMOGRANIN A; CHROMOGRANIN B; SECRETOGRANIN II; SECRETOGRANIN III; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BAROSTAT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FECES ANALYSIS; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH SURVEY; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; BIOLOGICAL MARKERS; CHROMOGRANINS; FECES; FEMALE; GASTROINTESTINAL TRANSIT; HUMANS; IRRITABLE BOWEL SYNDROME; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PHENOTYPE; QUESTIONNAIRES; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84857919909     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.458     Document Type: Article

References (68)

1. Dunlop SP, Jenkins D, Neal KR et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651-9. (Pubitemid 37500429)
2. Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-11.
3. Chadwick VS, Chen W, Shu D et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-83. (Pubitemid 34651421)
4. Cremon C, Gargano L, Morselli-Labate AM et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400.
5. Ö hman L, Isaksson S, Lundgren A et al. A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 980-6. (Pubitemid 41415745)
6. Törnblom H, Lindberg G, Nyberg B et al. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123: 1972-9. (Pubitemid 35408321)
7. Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702. (Pubitemid 38298317)
8. Guilarte M, Santos J, de Torres I et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56: 203-9.
9. O'Sullivan M, Clayton N, Breslin NP et al. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000; 12: 449-57.
10. Walker MM, Talley NJ, Prabhakar M et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2009; 29: 765-73.
11. Gwee KA, Leong YL, Graham C et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 400-6. (Pubitemid 29119338)
12. Chanat E, Huttner WB. Milieu-induced, selective aggregation of regulated secretory proteins in the trans-Golgi network. J Cell Biol 1991; 115: 1505-19. (Pubitemid 21909992)
13. Winkler H, Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 1992; 49: 497-528.
14. Portela-Gomes GM, Grimelius L, Stridsberg M. Secretogranin III in human neuroendocrine tumours: a comparative immunohistochemical study with chromogranins A and B and secretogranin II. Regul Pept 2010; 165: 30-5.
15. Hosaka M, Suda M, Sakai Y et al. Secretogranin III binds to cholesterol in the secretory granule membrane as an adapter for chromogranin A. J Biol Chem 2004; 279: 3627-34. (Pubitemid 38140604)
16. Hosaka M, Watanabe T, Sakai Y et al. Identification of a chromogranin A domain that mediates binding to secretogranin III and targeting to secretory granules in pituitary cells and pancreatic beta-cells. Mol Biol Cell 2002; 13: 3388-99. (Pubitemid 35191362)
17. Eriksson B, Oberg K. Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumors. Acta Oncol 1991; 30: 477-83.
18. Granberg D, Stridsberg M, Seensalu R et al. Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1999; 84: 2712-7. (Pubitemid 30641998)
19. Sciola V, Massironi S, Conte D et al. Plasma chromogranin A in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 867-71.
20. Sidhu R, McAlindon ME, Leeds JS et al. The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome. J Gastrointestin Liver Dis 2009; 18: 23-6.
21. Sidhu R, Drew K, McAlindon ME et al. Elevated serum chromogranin A in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD): a shared model for pathogenesis? Inflamm Bowel Dis 2010; 16: 361.
22. El-Salhy M, Lomholt-Beck B, Hausken T. Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome. Scand J Gastroenterol 2010; 45: 1435-9.
23. O'Donnell LJ, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ 1990; 300: 439-40. (Pubitemid 20069266)
24. Stridsberg M, Eriksson B, Janson ET. Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours. Regul Pept 2008; 148: 95-8.
25. Stridsberg M, Oberg K, Li Q et al. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995; 144: 49-59.
26. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70. (Pubitemid 13098606)
27. Derogatis LR, Rickels K, Rock AF. The SCL-90 and the MMPI: a step in the validation of a new self-report scale. Br J Psychiatry 1976; 128: 280-9.
28. Wiklund IK, Fullerton S, Hawkey CJ et al. An irritable bowel syndromespecific symptom questionnaire: development and validation. Scand J Gastroenterol 2003; 38: 947-54. (Pubitemid 37153623)
29. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
30. Jerndal P, Ringström G, Agerforz P et al. Gastrointestinal-specific anxiety: an important factor for severity of GI symptoms and quality of life in IBS. Neurogastroenterol Motil 2010; 22: 646-e179.
31. Labus JS, Bolus R, Chang L et al. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther 2004; 20: 89-97. (Pubitemid 38949810)
32. Labus JS, Mayer EA, Chang L et al. The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. Psychosom Med 2007; 69: 89-98. (Pubitemid 46148369)
33. Posserud I, Syrous A, Lindstrom L et al. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. Gastroenterology 2007; 133: 1113-23. (Pubitemid 47494459)
34. Sadik R, Abrahamsson H, Stotzer PO. Gender differences in gut transit shown with a newly developed radiological procedure. Scand J Gastroenterol 2003; 38: 36-42. (Pubitemid 36152862)
35. Helle KB. Regulatory peptides from chromogranin A and secretogranin II: putative modulators of cells and tissues involved in inflammatory conditions. Regul Pept 2010; 165: 45-51.
36. Bartolomucci A, Pasinetti GM, Salton SR. Granins as disease-biomarkers: translational potential for psychiatric and neurological disorders. Neuroscience 2010; 170: 289-97.
37. Barbara G, Wang B, Stanghellini V et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132: 26-37. (Pubitemid 46108761)
38. Ohashi K, Sato Y, Kawai M et al. Abolishment of TNBS-induced visceral hypersensitivity in mast cell deficient rats. Life Sci 2008; 82: 419-23.
39. Ghia JE, Crenner F, Metz-Boutigue MH et al. The effect of a chromogranin A-derived peptide (CgA4-16) in the writhing nociceptive response induced by acetic acid in rats. Life Sci 2004; 75: 1787-99. (Pubitemid 39070493)
40. Ghia JE, Crenner F, Metz-Boutigue MH et al. Effects of a chromogranin-derived peptide (CgA 47-66) in the writhing nociceptive response induced by acetic acid in rats. Regul Pept 2004; 119: 199-207. (Pubitemid 38553838)
41. Ghia JE, Pradaud I, Crenner F et al. Effect of acetic acid or trypsin application on rat colonic motility in vitro and modulation by two synthetic fragments of chromogranin A. Regul Pept 2005; 124: 27-35. (Pubitemid 39488338)
42. Ghia JE, Crenner F, Rohr S et al. A role for chromogranin A (4-16), a vasostatin-derived peptide, on human colonic motility. An in vitro study. Regul Pept 2004; 121: 31-9. (Pubitemid 38901059)
43. Solmaz M, Kavuk I, Sayar K. Psychological factors in the irritable bowel syndrome. Eur J Med Res 2003; 8: 549-56.
44. Whitehead WE, Crowell MD, Robinson JC et al. Effects of stressful life events on bowel symptoms: subjects with irritable bowel syndrome compared with subjects without bowel dysfunction. Gut 1992; 33: 825-30.
45. Kanamaru Y, Kikukawa A, Shimamura K. Salivary chromogranin-A as a marker of psychological stress during a cognitive test battery in humans. Stress 2006; 9: 127-31. (Pubitemid 44581954)
46. Lee T, Shimizu T, Iijima M et al. Evaluation of psychosomatic stress in children by measuring salivary chromogranin A. Acta Paediatr 2006; 95: 935-9. (Pubitemid 44181212)
47. Takatsuji K, Sugimoto Y, Ishizaki S et al. The effects of examination stress on salivary cortisol, immunoglobulin A, and chromogranin A in nursing students. Biomed Res 2008; 29: 221-4.
48. Hamaguchi T, Fukudo S, Kanazawa M et al. Changes in salivary physiological stress markers induced by muscle stretching in patients with irritable bowel syndrome. Biopsychosoc Med 2008; 2: 20.
49. Coutinho SV, Plotsky PM, Sablad M et al. Neonatal maternal separation alters stress-induced responses to viscerosomatic nociceptive stimuli in rat. Am J Physiol Gastrointest Liver Physiol 2002; 282: G307-16. (Pubitemid 34651687)
50. Barreau F, Ferrier L, Fioramonti J et al. Neonatal maternal deprivation triggers long term alterations in colonic epithelial barrier and mucosal immunity in rats. Gut 2004; 53: 501-6. (Pubitemid 38372973)
51. Söderholm JD, Yates DA, Gareau MG et al. Neonatal maternal separation predisposes adult rats to colonic barrier dysfunction in response to mild stress. Am J Physiol Gastrointest Liver Physiol 2002; 283: G1257-63. (Pubitemid 35351112)
52. Lopes LV, Marvin-Guy LF, Fuerholz A et al. Maternal deprivation aff ects the neuromuscular protein profile of the rat colon in response to an acute stressor later in life. J Proteomics 2008; 71: 80-8. (Pubitemid 351697864)
53. Cubeddu LX, O ' Connor DT, Parmer RJ. Plasma chromogranin A: a marker of serotonin release and of emesis associated with cisplatin chemotherapy. J Clin Oncol 1995; 13: 681-7.
54. Fischer-Colbrie R, Laslop A, Kirchmair R. Secretogranin II: molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Prog Neurobiol 1995; 46: 49-70.
55. Kahler CM, Schratzberger P, Kaufmann G et al. Transendothelial migration of leukocytes and signalling mechanisms in response to the neuropeptide secretoneurin. Regul Pept 2002; 105: 35-46. (Pubitemid 34164381)
56. Aung G, Niyonsaba F, Ushio H et al. Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and chemokines. Immunology 2010; 132: 527-39.
57. Prasad P, Yanagihara AA, Small-Howard AL et al. Secretogranin III directs secretory vesicle biogenesis in mast cells in a manner dependent upon interaction with chromogranin A. J Immunol 2008; 181: 5024-34.
58. Kruger PG, Mahata SK, Helle KB. Catestatin (CgA344-364) stimulates rat mast cell release of histamine in a manner comparable to mastoparan and other cationic charged neuropeptides. Regul Pept 2003; 114: 29-35. (Pubitemid 36588674)
59. Briolat J, Wu SD, Mahata SK et al. New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A. Cell Mol Life Sci 2005; 62: 377-85. (Pubitemid 40379251)
60. Lugardon K, Raffner R, Goumon Y et al. Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A. J Biol Chem 2000; 275: 10745-53. (Pubitemid 30212702)
61. Norlen P, Bernsand M, Konagaya T et al. ECL-cell histamine mobilization in conscious rats: effects of locally applied regulatory peptides, candidate neurotransmitters and inflammatory mediators. Br J Pharmacol 2001; 134: 1767-77. (Pubitemid 34038111)
62. Öhman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7: 163-73.
63. Mahata SK, O'Connor DT, Mahata M et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997; 100: 1623-33. (Pubitemid 27425790)
64. Angeletti RH, Aardal S, Serck-Hanssen G et al. Vasoinhibitory activity of synthetic peptides from the amino terminus of chromogranin A. Acta Physiol Scand 1994; 152: 11-9. (Pubitemid 24287114)
65. Schneitler C, Kahler C, Wiedermann CJ et al. Specific binding of a 125Isecretoneurin analogue to a human monocytic cell line. J Neuroimmunol 1998; 86: 87-91. (Pubitemid 28293953)
66. Kong C, Gill BM, Rahimpour R et al. Secretoneurin and chemoattractant receptor interactions. J Neuroimmunol 1998; 88: 91-8. (Pubitemid 28342908)
67. Fischer-Colbrie R, Lassmann H, Hagn C et al. Immunological studies on the distribution of chromogranin A and B in endocrine and nervous tissues. Neuroscience 1985; 16: 547-55. (Pubitemid 16210091)
68. Metz-Boutigue MH, Garcia-Sablone P, Hogue-Angeletti R et al. Intracellular and extracellular processing of chromogranin A. Determination of cleavage sites. Eur J Biochem 1993; 217: 247-57. (Pubitemid 23305293)